https://www.selleckchem.com/pr....oducts/elenestinib-p
8% versus 43.8%; P less then 0.001) in the primary prevention population. However, the prevalence of statin use was not statistically different in the LGB versus non-LGB respondents in the secondary prevention population. Adjusting for the covariates, the LGB participants were less likely to use statins than the non-LGB respondents in the primary prevention population (odds ratio, 0.37; 95% CI, 0.19-0.7. Conclusions Our results are the first to emphasize the urgent need for tailored, evidence-based cardiovascular disease
Like
Comment
Share
